Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
In a recent webinar, Future Proofing Cell & Gene Therapy: Strategies to Secure Your Leukapheresis Supply Chain, Heather Munoz, Principal of Global Market Development, and James
South Texas Blood & Tissue COO recognized for exceptional leadership and contributions to donor services and transfusion medicine. Audra Taylor, Chief Operating Officer of South
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Honorees recognized by the San Antonio Business Journal reflect innovation, leadership and impact across BioBridge Global and its subsidiaries. Four members of the team at
Emerging discoveries in blood group science highlight the need for advanced testing, donor diversity, and adaptable strategies across transfusion medicine and biotherapeutics. A new blood
Rohini Thevi Guntnur, Ray Rendon III, Joseph Higdon, Deidre Cacchillo, and Rogelio Zamilpa Therapeutic efficacy, reliability, and availability of cell, gene, and tissue-derived therapies have
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
BBG Advanced Therapies was recently highlighted in a GlobalData feature examining the emerging role of extracellular vesicles (EVs) in regenerative medicine and targeted drug delivery.
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Heather Munoz discusses how blood center infrastructure and flexible collection models are supporting the continued growth of cell and gene therapy. Heather Munoz, principal, global